ReViral Ltd., a clinical-stage company focused on developing novel, antiviral compounds that target respiratory syncytial virus (RSV), announced that Alex C. Sapir has been appointed Chief Executive Officer (CEO) and elected to the Board of Directors, effective June 10, 2019.
June 11, 2019
· 5 min read